← Incyte Corporation (INCY) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Incyte Corporation (INCY)
Services-Commercial Physical & Biological Research · market cap $24.9B · as of 2026-07-10
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-10-09 (est.)
Phase 3
Pipeline
20
programs
Upcoming events
8
next 90d+
Dossier
Ready
cached
Incyte Corporation (INCY) is a Wilmington, Delaware-based multinational pharma with a diversified pipeline spanning oncology, inflammatory, and hematologic diseases. At a $23.4B market cap and $117.26/share, the stock trades above the analyst consensus mean target of ~$111, supported by $3.46B net cash and a revenue trajectory that reached $5.14B in 2025. The next 12 months are dense with high-importance readouts, most critically two Phase 3 Ruxolitinib Cream data points and a Phase 3 Povorcitinib read in vitiligo.
The catalyst path
- 2026-10-09 (est.)Phase 3 · Ruxolitinib Creamimp 9/10
- 2026-10-27 (est.)Earningsimp 5/10
- 2026-11-05 (est.)Phase 2 · parsaclisib + itacitinibimp 7/10
- 2026-12-31 (est.)Phase 2 · R-CHOPimp 7/10
- 2027-04-27 (est.)Phase 2 · INCB123667imp 7/10
- 2027-04-27 (est.)Phase 3 · INCB123667imp 9/10
- 2027-04-30 (est.)Phase 3 · Ruxolitinib Creamimp 9/10
- 2027-06-01 (est.)Phase 2 · Ruxolitinibimp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| INCA034176 | Phase 3 | Chronic Graft-versus-host-disease |
| Povorcitinib | Phase 3 | NonSegmental Vitiligo |
| Ruxolitinib Cream | Phase 3 | Nonsegmental Vitiligo With Genital Involvement |
| INCB001158 | Phase 2 | Biliary Tract Cancer (BTC) |
| INCB177054 | Phase 2 | Solid Tumors |
| ICS-LABA | Phase 2 | Moderate to Severe Asthma |
| Itacitinib | Phase 3 | MPN (Myeloproliferative Neoplasms) |
| pembrolizumab + epacadostat | Phase 3 | Melanoma |
| Pemigatinib | Phase 2 | Non-Small Cell Lung Cancer (NSCLC) |
| Extracorporeal photopheresis (ECP) | Phase 3 | Graft-versus-host Disease (GVHD) |
| Ruxolitinib 25 mg | Phase 2 | Multiple Myeloma |
| Asparaginase Erwinia Chrysanthemi | Phase 2 | Leukemia |
| ruxolitinib tablets | Phase 3 | Polycythemia Vera |
| INCB013739 | Phase 2 | Type 2 Diabetes |
| INCB000928 | Phase 2 | Anemia |
| Ruxolitinib phosphate cream | Phase 2 | Psoriasis |
| INCB054707 | Phase 2 | Hidradenitis Suppurativa |
| Parsaclisib | Phase 2 | B-Cell Malignancies |
| Ponatinib | Phase 2 | Philadelphia Positive |
| Ruxolitinib 0.15% Cream QD | Phase 2 | Atopic Dermatitis |
Price & technical context
3-month
+0.5%
6-month
+21.1%
12-month
+34.7%
52-wk range
$83.80–$129.93
vs 50-day MA
-6.0%
vs 200-day MA
+8.7%
Realized vol
34.0%
Max drawdown
-33.8%
Daily closes through 2026-10-02. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for INCY (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.